GLP-1 Newsroom is your go-to source for breaking news, expert updates, trends, products, and real-world insights on everything related to GLP-1 medications, journeys, and diets.
With demand for GLP-1 medications like semaglutide and tirzepatide soaring, clinical trials have quietly become one of the only ways some people can access treatment, especially if they’re uninsured or can’t afford retail prices.
But before you go signing up for an experimental dose of the next Ozempic or peptide agonist, there are a few important things to understand.
In this article, we'll talk about what clinical trials are, their pros and cons, what to expect, and how to
Retatrutide is being called the “triple threat” of weight loss drugs—and it’s not even on the market yet. Developed by Eli Lilly, the same pharmaceutical giant behind tirzepatide (better known as Mounjaro and Zepbound), this new contender is generating buzz for its potential to help people lose more weight, faster.
